PMID- 16135392
OWN - NLM
STAT- MEDLINE
DCOM- 20060227
LR  - 20151119
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 24
IP  - 3
DP  - 2006 Jan 16
TI  - Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.
PG  - 244-53
AB  - DNA vaccines show efficacy in many preclinical models, but these results have not 
      yet translated to consistent clinical efficacy. Co-administration of molecularly 
      encoded adjuvants is one approach that may enable DNA vaccines to achieve 
      enhanced immune response induction in humans. Interleukin-18 (IL-18) is a 
      Th1-type cytokine that has been shown to augment the activity of DNA vaccines in 
      some preclinical models. A prostate-specific antigen (PSA) DNA vaccine was tested 
      in a mouse tumor model system to explore the impact of co-administration of a 
      pIL-18 plasmid. Low doses of the pPSA vaccine were not capable of inducing tumor 
      protection, but when pIL-18 was co-administered, complete tumor protection was 
      observed in all mice. Tumor protection was mediated by both CD4(+) and CD8(+) T 
      cells. Detailed analysis of the immune response in mice immunized with either 
      pPSA or pPSA/pIL-18 demonstrated that pIL-18 skewed the PSA-specific immune 
      response toward Th1. More importantly, stronger CD4(+) and CD8(+) T cell 
      responses developed in the pPSA/pIL-18-immunized mice, with faster kinetics. 
      These results suggest that IL-18 is a powerful adjuvant molecule that can enhance 
      the development of antigen-specific immunity and vaccine efficacy.
FAU - Marshall, Deborah J
AU  - Marshall DJ
AD  - Centocor, Inc., 145 King of Prussia Road, Radnor, PA 19087, USA. 
      dmarsha1@cntus.jnj.com
FAU - Rudnick, Kelly A
AU  - Rudnick KA
FAU - McCarthy, Stephen G
AU  - McCarthy SG
FAU - Mateo, Lani R San
AU  - Mateo LR
FAU - Harris, Michael C
AU  - Harris MC
FAU - McCauley, Christine
AU  - McCauley C
FAU - Snyder, Linda A
AU  - Snyder LA
LA  - eng
PT  - Journal Article
DEP - 20050815
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antimetabolites)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin-18)
RN  - 0 (Vaccines, DNA)
RN  - G34N38R2N1 (Bromodeoxyuridine)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antibody Specificity
MH  - Antimetabolites
MH  - Bromodeoxyuridine
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cytokines/analysis/biosynthesis
MH  - Female
MH  - Immunoglobulin G/analysis/biosynthesis
MH  - Interleukin-18/*pharmacology
MH  - Kinetics
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasms/immunology/prevention & control
MH  - Plasmids/genetics
MH  - Stimulation, Chemical
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Th1 Cells/*immunology
MH  - Vaccines, DNA/immunology
EDAT- 2005/09/02 09:00
MHDA- 2006/02/28 09:00
CRDT- 2005/09/02 09:00
PHST- 2005/02/11 00:00 [received]
PHST- 2005/07/29 00:00 [accepted]
PHST- 2005/09/02 09:00 [pubmed]
PHST- 2006/02/28 09:00 [medline]
PHST- 2005/09/02 09:00 [entrez]
AID - S0264-410X(05)00771-1 [pii]
AID - 10.1016/j.vaccine.2005.07.087 [doi]
PST - ppublish
SO  - Vaccine. 2006 Jan 16;24(3):244-53. doi: 10.1016/j.vaccine.2005.07.087. Epub 2005 
      Aug 15.